Skip to content
The Policy VaultThe Policy Vault

Tibsovo (ivosidenib) — Medica

Myelodysplastic Syndrome

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has isocitrate dehydrogenase-1 (IDH1) mutation-positive disease
  • Patient has relapsed or refractory disease

Approval duration

1 year